This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pfeiffer, J. K.
Right arrow Articles by Kirkegaard, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pfeiffer, J. K.
Right arrow Articles by Kirkegaard, K.

 Previous Article  |  Next Article 

Journal of Virology, February 2005, p. 2346-2355, Vol. 79, No. 4
0022-538X/05/$08.00+0     doi:10.1128/JVI.79.4.2346-2355.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Ribavirin Resistance in Hepatitis C Virus Replicon-Containing Cell Lines Conferred by Changes in the Cell Line or Mutations in the Replicon RNA

Julie K. Pfeiffer1 and Karla Kirkegaard1*

Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California1

Received 3 August 2004/ Accepted 5 October 2004

Ribavirin (RBV), used in combination with alpha interferon to treat hepatitis C virus (HCV) infections, is a guanosine nucleotide analog that can increase the error rate of viral RNA-dependent RNA polymerases, imbalance intracellular nucleotide pools, and cause toxicity in many cell types. To determine potential mechanisms of RBV resistance during HCV RNA replication, we passaged HCV replicon-containing cell lines in the presence of increasing concentrations of RBV. RBV-resistant, HCV replicon-containing cell lines were generated, and the majority of RBV resistance was found to be conferred by changes in the cell lines. The resistant cell lines were defective in RBV import, as measured by [3H]RBV uptake experiments. These cell lines displayed reduced RBV toxicity and reduced error accumulation during infection with poliovirus, whose replication is known to be sensitive to RBV-induced error. For one RBV-resistant isolate, two mutations in the replicon RNA contributed to the observed phenotype. Two responsible mutations resided in the C-terminal region of NS5A, G404S, and E442G and were each sufficient for low-level RBV resistance. Therefore, RBV resistance in HCV replicon cell lines can be conferred by changes in the cell line or by mutations in the HCV replicon.

* Corresponding author. Mailing address: Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305. Phone: (650) 498-7075. Fax: (650) 498-7147. E-mail: karlak{at}leland.stanford.edu.

Journal of Virology, February 2005, p. 2346-2355, Vol. 79, No. 4
0022-538X/05/$08.00+0     doi:10.1128/JVI.79.4.2346-2355.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Ibarra, K. D., Pfeiffer, J. K. (2009). Reduced Ribavirin Antiviral Efficacy via Nucleoside Transporter-Mediated Drug Resistance. J. Virol. 83: 4538-4547 [Abstract] [Full Text]  
  • Arias, A., Arnold, J. J., Sierra, M., Smidansky, E. D., Domingo, E., Cameron, C. E. (2008). Determinants of RNA-Dependent RNA Polymerase (In)fidelity Revealed by Kinetic Analysis of the Polymerase Encoded by a Foot-and-Mouth Disease Virus Mutant with Reduced Sensitivity to Ribavirin. J. Virol. 82: 12346-12355 [Abstract] [Full Text]  
  • Heck, J. A., Lam, A. M. I., Narayanan, N., Frick, D. N. (2008). Effects of Mutagenic and Chain-Terminating Nucleotide Analogs on Enzymes Isolated from Hepatitis C Virus Strains of Various Genotypes. Antimicrob. Agents Chemother. 52: 1901-1911 [Abstract] [Full Text]  
  • Tellinghuisen, T. L., Foss, K. L., Treadaway, J. C., Rice, C. M. (2008). Identification of Residues Required for RNA Replication in Domains II and III of the Hepatitis C Virus NS5A Protein. J. Virol. 82: 1073-1083 [Abstract] [Full Text]  
  • Tellinghuisen, T. L., Evans, M. J., von Hahn, T., You, S., Rice, C. M. (2007). Studying Hepatitis C Virus: Making the Best of a Bad Virus. J. Virol. 81: 8853-8867 [Full Text]  
  • Robida, J. M., Nelson, H. B., Liu, Z., Tang, H. (2007). Characterization of Hepatitis C Virus Subgenomic Replicon Resistance to Cyclosporine In Vitro. J. Virol. 81: 5829-5840 [Abstract] [Full Text]  
  • Wohnsland, A., Hofmann, W. P., Sarrazin, C. (2007). Viral Determinants of Resistance to Treatment in Patients with Hepatitis C. Clin. Microbiol. Rev. 20: 23-38 [Abstract] [Full Text]  
  • Kato, T., Date, T., Miyamoto, M., Sugiyama, M., Tanaka, Y., Orito, E., Ohno, T., Sugihara, K., Hasegawa, I., Fujiwara, K., Ito, K., Ozasa, A., Mizokami, M., Wakita, T. (2005). Detection of Anti-Hepatitis C Virus Effects of Interferon and Ribavirin by a Sensitive Replicon System. J. Clin. Microbiol. 43: 5679-5684 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»